This company has been marked as potentially delisted and may not be actively trading. G1 Therapeutics (GTHX) Short Interest Ratio & Short Volume Add Compare Share Share Short Interest Stock AnalysisBuy This Stock G1 Therapeutics Short Interest DataG1 Therapeutics (GTHX) has a short interest of 3.41 million shares. This marks a -22.32% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.7, indicating that it would take 1.7 days of the average trading volume of 1.70 million shares to cover all short positions.Current Short Interest3,410,000 sharesPrevious Short Interest4,390,000 sharesChange Vs. Previous Month-22.32%Dollar Volume Sold Short$24.25 millionShort Interest Ratio1.7 Days to CoverLast Record DateAugust 31, 2024Outstanding Shares52,281,000 sharesPercentage of Shares Shorted6.52%Today's Trading Volume0 sharesAverage Trading Volume1,701,154 sharesToday's Volume Vs. Average0% Short Selling G1 Therapeutics? Sign up to receive the latest short interest report for G1 Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartGTHX Short Interest Over TimeGTHX Days to Cover Over TimeGTHX Percentage of Float Shorted Over Time G1 Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 8/31/20243,410,000 shares $24.25 million -22.3%N/A1.7 $7.11 8/15/20244,390,000 shares $31.17 million -23.9%N/A2.2 $7.10 7/31/20245,770,000 shares $24.75 million -17.9%N/A2.5 $4.29 7/15/20247,030,000 shares $22.78 million +23.6%N/A4.6 $3.24 6/30/20245,690,000 shares $12.97 million +16.4%N/A3.8 $2.28 6/15/20244,890,000 shares $13.59 million +20.4%N/A3.4 $2.78 5/31/20244,060,000 shares $13.40 million +13.1%N/A3.1 $3.30 5/15/20243,590,000 shares $16.84 million +26.9%N/A2.6 $4.69 4/30/20242,830,000 shares $10.67 million +16.9%N/A2.5 $3.77 4/15/20242,420,000 shares $10.43 million -12.3%N/A1.9 $4.31 Get the Latest News and Ratings for GTHX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 3/31/20242,760,000 shares $11.92 million +2.6%N/A1.9 $4.32 3/15/20242,690,000 shares $8.37 million -7.6%N/A1.9 $3.11 2/29/20242,910,000 shares $9.66 million -12.6%N/A1.5 $3.32 2/15/20243,330,000 shares $7.99 million +27.6%N/A1.8 $2.40 1/31/20242,610,000 shares $10.31 million -19.7%N/A1.8 $3.95 1/15/20243,250,000 shares $10.40 million +16.9%N/A2.4 $3.20 12/31/20232,780,000 shares $8.48 million +5.3%N/A2.2 $3.05 12/15/20232,640,000 shares $7.68 million +9.1%N/A2.3 $2.91 11/30/20232,420,000 shares $4.55 million -2.8%N/A3.1 $1.88 11/15/20232,490,000 shares $4.06 million +2.1%N/A4.8 $1.63 10/31/20232,440,000 shares $4.03 million -6.5%N/A4.4 $1.65 10/15/20232,610,000 shares $2.98 million -5.8%N/A3.4 $1.14 9/30/20232,770,000 shares $3.99 million -4.5%N/A3.4 $1.44 9/15/20232,900,000 shares $4.47 million -1.0%N/A3.5 $1.54 8/31/20232,930,000 shares $4.89 million No ChangeN/A3.3 $1.67 8/15/20232,930,000 shares $5.48 million -10.1%N/A3 $1.87 7/31/20233,260,000 shares $7.82 million +4.5%N/A3.2 $2.40 7/15/20233,120,000 shares $7.52 million +1.0%N/A3.6 $2.41 6/30/20233,090,000 shares $7.69 million +20.2%N/A3.9 $2.49 6/15/20232,570,000 shares $7.27 million -13.2%N/A3.1 $2.83 5/31/20232,960,000 shares $7.52 million -5.1%N/A3.3 $2.54 5/15/20233,120,000 shares $9.11 million -5.7%N/A3.3 $2.92 4/30/20233,310,000 shares $9.50 million -12.4%N/A2.8 $2.87 4/15/20233,780,000 shares $10.02 million -10.2%N/A3.2 $2.65 3/31/20234,210,000 shares $11.28 million +14.7%N/A3.4 $2.68 3/15/20233,670,000 shares $12.00 million +28.3%N/A2.9 $3.27 2/28/20232,860,000 shares $10.35 million -6.2%N/A2.2 $3.62 2/15/20233,050,000 shares $11.19 million -2.2%N/A2.3 $3.67 1/31/20233,120,000 shares $24.90 million +1.0%N/A2.7 $7.98 1/15/20233,090,000 shares $19.53 million +20.2%N/A2.7 $6.323..2..1.. AI 2.0 ignition (don’t sleep on this) (Ad)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 12/30/20222,570,000 shares $13.96 million -46.1%N/A2.3 $5.43 12/15/20224,770,000 shares $29.67 million +5.8%N/A4.3 $6.22 11/30/20224,510,000 shares $26.88 million -26.8%10.9%4 $5.96 11/15/20226,160,000 shares $55.01 million -18.2%14.9%6 $8.93 10/31/20227,530,000 shares $80.27 million +7.0%21.5%8.5 $10.66 10/15/20227,040,000 shares $78.21 million +9.7%20.2%7.3 $11.11 9/30/20226,420,000 shares $80.19 million +65.9%18.4%6.2 $12.49 9/15/20223,870,000 shares $59.79 million +11.9%11.1%3.5 $15.45 8/31/20223,460,000 shares $50.20 million -8.0%9.9%3 $14.51 8/15/20223,760,000 shares $49.26 million -20.7%10.8%3.1 $13.10 7/31/20224,740,000 shares $39.48 million -0.6%13.6%3.6 $8.33 7/15/20224,770,000 shares $36.06 million -8.5%14.4%4 $7.56 6/30/20225,210,000 shares $25.74 million -32.8%15.7%4.7 $4.94 6/15/20227,750,000 shares $33.09 million +6.9%23.3%7.1 $4.27 5/31/20227,250,000 shares $35.24 million +13.3%21.8%8 $4.86 5/15/20226,400,000 shares $29.50 million -2.4%19.3%7.5 $4.61 4/30/20226,560,000 shares $33.72 million +2.5%19.8%8.5 $5.14 4/15/20226,400,000 shares $45.31 million +1.1%19.3%8.1 $7.08 3/31/20226,330,000 shares $48.11 million -15.8%N/A7.7 $7.60 3/15/20227,520,000 shares $58.28 million -5.7%22.6%9.1 $7.75 2/28/20227,970,000 shares $84.56 million -3.0%24.0%9.8 $10.61 2/15/20228,220,000 shares $85.57 million -2.6%24.9%9.3 $10.41 1/31/20228,440,000 shares $85.08 million -5.3%25.5%9.5 $10.08 1/15/20228,910,000 shares $90.08 million -1.0%N/A9.8 $10.11 12/31/20219,000,000 shares $91.89 million -3.1%27.4%10 $10.21 12/15/20219,290,000 shares $99.12 million +2.9%28.3%9.6 $10.67 11/30/20219,030,000 shares $116.49 million +0.8%27.5%9.6 $12.90 11/15/20218,960,000 shares $130.91 million +0.9%26.6%9.9 $14.61 10/29/20218,880,000 shares $128.67 million +5.2%26.3%9.8 $14.49 10/15/20218,440,000 shares $107.78 million -6.4%25.1%9.7 $12.77 9/30/20219,020,000 shares $121.05 million +22.7%26.9%8.8 $13.42 9/15/20217,350,000 shares $102.46 million -3.7%21.9%7.4 $13.94 8/31/20217,630,000 shares $115.37 million +1.2%22.8%7.3 $15.12 8/13/20217,540,000 shares $108.27 million +2.6%22.5%6.7 $14.36 7/30/20217,350,000 shares $127.23 million +20.1%21.9%6.6 $17.31 7/15/20216,120,000 shares $116.89 million +5.0%18.4%5.3 $19.10 6/30/20215,830,000 shares $127.91 million -2.7%17.5%5.7 $21.94 6/15/20215,990,000 shares $130.88 million -4.8%18.0%5.9 $21.85 5/28/20216,290,000 shares $136.62 million -2.2%18.9%6.3 $21.72 5/14/20216,430,000 shares $133.04 million -8.8%19.3%5.8 $20.69 4/30/20217,050,000 shares $154.54 million +1.3%21.1%4.9 $21.92 4/15/20216,960,000 shares $171.91 million -6.5%21.1%4.6 $24.70 3/31/20217,440,000 shares $171.05 million -2.9%23.3%4.7 $22.99 3/15/20217,660,000 shares $178.86 million +21.0%24.0%5 $23.35 2/26/20216,330,000 shares $141.57 million +21.3%20.5%3.9 $22.37 2/12/20215,220,000 shares $170.12 million -3.0%18.7%3.2 $32.59 1/29/20215,380,000 shares $121.37 million -10.8%19.4%3.8 $22.56 1/15/20216,030,000 shares $124.64 million -9.5%21.8%4.6 $20.67 12/31/20206,660,000 shares $122.94 million -9.5%24.0%5.4 $18.46 12/15/20207,360,000 shares $144.22 million -2.9%26.3%6.1 $19.603..2..1.. AI 2.0 ignition (don’t sleep on this) (Ad)I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 11/30/20207,580,000 shares $108.39 million +14.2%27.1%6.6 $14.30 11/15/20206,640,000 shares $84.86 million -17.7%23.8%7.5 $12.78 10/30/20208,070,000 shares $90.30 million +8.0%28.8%10.4 $11.19 10/15/20207,470,000 shares $100.10 million +9.1%26.7%10.2 $13.40 9/30/20206,850,000 shares $79.12 million +39.5%24.5%9.9 $11.55 9/15/20204,910,000 shares $76.89 million +8.9%17.6%7.4 $15.66 8/31/20204,510,000 shares $69.23 million +3.2%16.1%7.4 $15.35 8/14/20204,370,000 shares $69.22 million +1.6%15.7%7 $15.84 7/31/20204,300,000 shares $63.08 million +19.8%15.5%7.1 $14.67 7/15/20203,590,000 shares $73.63 million +14.0%13.0%6.5 $20.51 6/30/20203,150,000 shares $76.42 million +2.9%11.4%6 $24.26 6/15/20203,060,000 shares $56.43 million No Change11.1%6.4 $18.44 5/29/20203,060,000 shares $51.93 million +6.3%11.1%6.5 $16.97 GTHX Short Interest - Frequently Asked Questions What is G1 Therapeutics' current short interest? Short interest is the volume of G1 Therapeutics shares that have been sold short but have not yet been closed out or covered. As of August 31st, investors have sold 3,410,000 shares of GTHX short. Learn More on G1 Therapeutics' current short interest. What is a good short interest ratio for G1 Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. GTHX shares currently have a short interest ratio of 2.0. Learn More on G1 Therapeutics's short interest ratio. Is G1 Therapeutics' short interest increasing or decreasing? G1 Therapeutics saw a decline in short interest in August. As of August 31st, there was short interest totaling 3,410,000 shares, a decline of 22.3% from the previous total of 4,390,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does G1 Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to G1 Therapeutics: Mesoblast Limited (2.10%), Structure Therapeutics Inc. (16.78%), Janux Therapeutics, Inc. (19.51%), Evotec SE (0.21%), ARS Pharmaceuticals, Inc. (29.82%), Adaptive Biotechnologies Co. (6.02%), Vera Therapeutics, Inc. (12.17%), Dyne Therapeutics, Inc. (13.07%), ANI Pharmaceuticals, Inc. (9.23%), Ocular Therapeutix, Inc. (8.15%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.11 billion), Canadian Natural Resources Limited ($4.04 billion), Suncor Energy Inc. ($3.19 billion), Aptiv PLC ($2.56 billion), Paychex, Inc. ($2.48 billion), Cencora, Inc. ($2.28 billion), Onsemi ($2.08 billion), Moderna, Inc. ($1.98 billion), Tractor Supply ($1.93 billion), and International Paper ($1.93 billion). View all of the most shorted stocks. What does it mean to sell short G1 Therapeutics stock? Short selling GTHX is an investing strategy that aims to generate trading profit from G1 Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against G1 Therapeutics? A short squeeze for G1 Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of GTHX, which in turn drives the price of the stock up even further. How often is G1 Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including GTHX, twice per month. The most recent reporting period available is August, 31 2024. More Short Interest Resources from MarketBeat Related Companies Mesoblast Short Squeeze Structure Therapeutics Short Squeeze Janux Therapeutics Short Squeeze Evotec Short Squeeze ARS Pharmaceuticals Short Squeeze Adaptive Biotechnologies Short Squeeze Vera Therapeutics Short Squeeze Dyne Therapeutics Short Squeeze ANI Pharmaceuticals Short Squeeze Ocular Therapeutix Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:GTHX) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredDo You Believe In President Trump? Answer This 1 QuestionThey said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share G1 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GTHX Stock Free GTHX Stock Alerts